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Abstract
Background: Frailty is the loss of ability to withstand a physiological stressor and is associated with multiple
adverse outcomes in older people. Trials to prevent or ameliorate frailty are in their infancy. A range of different
outcome measures have been proposed, but current measures require either large sample sizes, long follow-up, or
do not directly measure the construct of frailty.
Methods: We propose a composite outcome for frailty prevention trials, comprising progression to the frail state,
death, or being too unwell to continue in a trial. To determine likely event rates, we used data from the English
Longitudinal Study for Ageing, collected 4 years apart. We calculated transition rates between non-frail, prefrail, frail
or loss to follow up due to death or illness. We used Markov state transition models to interpolate one- and two-
year transition rates and performed sample size calculations for a range of differences in transition rates using
simple and composite outcomes.
Results: The frailty category was calculable for 4650 individuals at baseline (2226 non-frail, 1907 prefrail, 517 frail); at
follow up, 1282 were non-frail, 1108 were prefrail, 318 were frail and 1936 had dropped out or were unable to
complete all tests for frailty. Transition probabilities for those prefrail at baseline, measured at wave 4 were
respectively 0.176, 0.286, 0.096 and 0.442 to non-frail, prefrail, frail and dead/dropped out. Interpolated transition
probabilities were 0.159, 0.494, 0.113 and 0.234 at two years, and 0.108, 0.688, 0.087 and 0.117 at one year. Required
sample sizes for a two-year outcome in a two-arm trial were between 1040 and 7242 for transition from prefrailty
to frailty alone, 246 to 1630 for transition to the composite measure, and 76 to 354 using the composite measure
with an ordinal logistic regression approach.
Conclusion: Use of a composite outcome for frailty trials offers reduced sample sizes and could ameliorate the
effect of high loss to follow up inherent in such trials due to death and illness.
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Background
Frailty is a state of decreased reserve such that a minor
perturbation (such as a mild illness or injury) causes
major physiological decompensation and worsening of
health [1]. Frailty predicts multiple adverse outcomes in
older people. Including falls, hospitalisation, disability, a
need for care, and earlier death. Although long recog-
nised as a clinical concept, frailty was not effectively
operationalised until the early 2000s [2, 3]. Since then,
uptake of frailty measures into clinical practice has in-
creased rapidly, both in specialist services for older
people, but more recently in primary care services and
in organ-specific specialist services [4, 5]. Despite this
widespread assessment of frailty in clinical practice,
much less is known about what interventions are effect-
ive in reversing, or preventing progression of, the frailty
state. Comparatively few randomised controlled trials
have been conducted in this area to date, and most trials
have focussed on exercise-based programmes [6–9].
Perhaps understandably given the nascent nature of this
research field, there is no consensus on the most appropri-
ate outcome measure to use in frailty intervention trials –
particularly in early-phase trials that are essential in identi-
fying the most promising candidate interventions to take
forward to large-scale testing. Measures of physical per-
formance have been used in some trials; examples include
the Short Physical Performance Battery (SPPB), which has
been advocated by the SPRINTT consortium as a surrogate
for identifying frailty [10, 11] and gait speed, used in a re-
cent trial of metformin in prefrail individuals [12] and as a
secondary outcome in a recent exercise trial [13]. An alter-
native approach is to use measures of activity limitation as
the main outcome. Inability to complete a 400m walk
within 15min was the primary outcome for the SPRINTT
trial, with the authors arguing that this measure denotes
progression of frailty to disability. Such approaches have
the advantage of using well-characterised, simple measures,
but they depart conceptually from the original definition of
frailty – “a multidimensional syndrome characterised by de-
creased reserve and diminished resistance to stressors” [14].
Use of single physical performance measures such as the
SPPB to define frailty restricts the definition of frailty to im-
pairment of neuromuscular function. Even use of an aer-
obic measure of physical performance (such as the 6 min
walk or 400m walk), which has the advantage of including
cardiorespiratory function, does not encompass other as-
pects of the frailty syndrome such as impaired energy
homeostasis or multisystem dysfunction.
There are two main ways of operationalising the frailty
syndrome that might be used as direct outcome measures
in clinical trials. The first is the deficit accumulation index
[3]. This can now be assessed by automated means from
routinely collected clinical data [15] but many of the deficits
from which the index is built are based on diagnoses – and
are thus unlikely to be reversed by intervention. Deficit ac-
cumulation indices may therefore be a useful way of identi-
fying those with the frailty syndrome but may not be useful
as an outcome measure – particularly over short time pe-
riods. The alternative is to use a measure of phenotypic
frailty, of which the Fried frailty score is the most widely
used [2]. Whilst physical performance measures form part
of this score, they are complemented by a measure of energy
homeostasis (weight loss), activity, and exhaustion – all of
which more closely reflect the impairment of whole-body
homeostasis alluded to in consensus definitions of frailty.
Two important issues complicate the use of frailty as
measured by the Fried phenotype. Firstly, transition rates
from prefrailty to frailty are relatively low (18% over 4
years in a recent meta-analysis) [16], thus large sample
sizes are likely to be required to detect differences in tran-
sition rates. Furthermore, transition rates from frailty to
death are high – thus the time spent in the frail state may
be comparatively short, and dropout rates (due to death
or illness) are thus also likely to be high. Treating the
Fried phenotypic score as a continuous variable has been
used as an alternative approach, although it is question-
able whether this is appropriate way to analyse such a
variable given that a one-unit step may not be a constant
quantity, and may vary depending on what components
are included and where in the score distribution the value
is located. Even using this approach, sample sizes of 500–
600 are required to detect a one-point difference [17].
To enable sample size calculations to be conducted for
frailty prevention trials, data are required on rates of tran-
sition between prefrailty and frailty in target populations
under a range of assumptions. The aim of this paper is to
calculate these transition rates using data from the English
Longitudinal Study of Ageing (ELSA), and to compare re-
quired sample sizes for simple frailty transitions, a com-
posite measure of progression to frailty, death or dropout.
Methods
Derivation of transition rates for different frailty states
To study transition rates between robust, prefrail and frail
states, we calculated phenotypic frailty scores after the
method of Fried et al. [2] using data from ELSA waves 2
(collected 2004) and 4 (collected 2008) [18]. We included
participants aged 60 and over at the time of the wave 2
data collection. Participants in these waves underwent a
nurse-led assessment, at which grip strength, weight and
gait speed were collected allowing a phenotypic frailty
score to be derived. The phenotypic frailty score was de-
rived using the same methods as previously used in ELSA,
using the components first described by Fried et al. [2,
19]. Detailed methods for deriving each component of the
frailty score are given in Table 1. Maximal handgrip
strength was measured using a Smedley dynamometer,
with results adjusted for body mass index. Walk speed
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was measured over a four metre course. Two attempts
were recorded, with the highest walk speed used and ad-
justed for height. Weight was measured to the nearest
kilogram, and the difference in weight between waves 0
and 2 was calculated. A physical activity index was calcu-
lated from self-reported frequency of mild, moderate and
vigorous activity, with weights of 1.5, 3 and 6 METS re-
spectively [20], multiplied by frequency for each activity
category: Never (× 0), 1–3 times per month (× 2), once a
week (× 4) or more than once a week (× 8). This approach
allowed a more finely graduated estimate of physical activ-
ity than the derived four-state summary variable available
in the ELSA dataset. Finally, self-reported exhaustion was
measured using answers to two questions from the CES-D
questionnaire: ‘everything I did was an effort’ and ‘I could
not get going’. One point was awarded to those in the low-
est sex-specific fifth for adjusted grip strength, adjusted
walk speed and self-reported activity; one point was
awarded if either self-reported exhaustion question was
positive, and one point was awarded if the BMI was <
18.5 kg/m2 or for > 10% weight loss since the last meas-
urement in ELSA. This dual approach for weight was
adopted to minimise the impact of missing prior weight
measurements. In all cases, the thresholds for defining
each component were derived from the wave 2 data and
applied without change to the wave 4 data. Measurements
on all five frailty components had to be available at Wave
2 for an individual to have a frailty score calculated and to
be included in the analyses. This approach is necessary for
accurate coding of prefrailty, and also most accurately re-
flects the data state likely to be present at enrolment into
frailty trials.
Analyses - frailty transitions in ELSA
For all analyses, only those individuals with complete data
for all five components of the frailty score were included.
Table 1 Derivation of frailty score components in ELSA
Component Definition
Weight loss BMI < 18.5 kg/m2 OR > 10% weight loss since last wave
Exhaustion Positive answer to either CES-D question (‘everything I did was an effort’ or ‘I
could not get going’
Low grip strength (adjusted for BMI)
Males: Grip adjusted for BMI = Maximum grip – ((BMI-27.6)× 0.31)
Females: Grip adjusted for BMI = Maximum grip – ((BMI-27.9)× 0.07)
Low grip strength was defined as values in the lowest quintile at wave 2,
for males and females separately:
M < 31.12 kg
F < 17.60 kg
Low gait speed (adjusted for height)
Males: Gait speed adjusted for BMI = Gait speed – ((height-
172)×0.00941)
Females: Gait speed adjusted for BMI = Gait speed – ((height-158)×
0.010)
Low gait speed was defined as values in the lowest quintile at wave 2,
for males and females separately.
M < 0.691 m/s
F < 0.619 m/s
Low activity M < 16.5 activity units
F < 13.5 activity units
Fig. 1 Markov model for frailty state transitions
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This choice is likely to exclude some people who are par-
ticularly frail or unwell (as shown in other studies of
phenotypic frailty scores) [21], but it reflects more accur-
ately the population likely to enter trials to treat frailty or
prefrailty (for whom a complete frailty score at baseline
would be obtained). Summary statistics for this dataset
were calculated using SPSS v22 (IBM, New York, USA).
Analyses - interpolation of transition rates at 1 and 2
years
The span between waves where the frailty phenotype
was evaluable in ELSA was 4 years. Given the expense of
conducting four-year follow up in trials, allied to the
high dropout rate over this time period, shorter follow
up times (1 or 2 years) are desirable for frailty trials. To
interpolate the transition rates at 1 and 2 years, a Mar-
kov state transition model was constructed (Fig. 1) with
probabilities fitted from the ELSA 4 year follow up data.
The square root of the transition probability matrix was
calculated to derive two-year transition probabilities, and
the fourth-root of the transition probability matrix was
calculated to derive the one-year transition probabilities.
We defined P as the transition matrix for the four-year
transition probabilities with P_ij, i, j∈{1,2,3,4,5} repre-
senting the probability of transitioning from state i to
state j in 4 years. The states were robust (1), prefrail (2),
frail (3), dead or too ill to continue in study (4), dropped
out for reasons other than being too ill (5). We then
used the matrix decomposition to express P as ZAZ^(−
1) where Z is a matrix with the eigenvectors of P as the
columns, and A is a diagonal matrix with (positive) ei-
genvalues along the diagonal. This allowed us to find
matrix square- and fourth-root as ZA^(1/2) Z^(− 1) and
ZA^(1/4) Z^(− 1) respectively [22]. These were taken as
estimates of the one- and two-year transition probabil-
ities and the second row of each extracted as the transi-
tion probabilities for pre-frail patients. This process was
performed in R version 3.5 using the functions ‘eigen’ to
extract the eigenvectors and eigenvalues of the original
four-year transition matrix, and ‘ginv’ to find the inverse
of the matrix of eigenvectors. It was not possible from
ELSA data to determine whether participants who
dropped out did so because they were too ill or for other
reasons. We therefore considered three potential as-
sumptions for participants who dropped out: 1) all drop-
out was due to being too ill to continue; 2) 50% of
dropout was due to being too ill; 3) all dropout was for
reasons other than being too ill.
Analyses - calculation of sample sizes
For all sample size calculations, a two-sided alpha of 0.05
and a power of 0.90 was used. No consensus exists for the
degree of reduction in the risk of transition to frailty that
is clinically important, thus values for a range of relative
Table 2 Prevalence of frailty components in wave 2 and wave 4 of ELSA
Wave 2 (n = 5344) Wave 4 (n = 3088)
Mean age (years) (SD) All 71.3 (8.2) 69.9 (7.2)
With any missing data 74.2 (9.7) 73.9 (8.3)
Male sex (%) All 2389 (44.7) 1368 (44.3)
With any missing data 299/694 (43.0) 138/374 (36.9)
Weight loss / low BMI (%) Calculable 391/5107 (7.7) 282/3088 (9.1)
Missing 237/5344 (4.4) 0/3088 (0)
Low grip strength (%) Calculable 1049/5251 (20.0) 689/2888 (23.9)
Missing 93/5344 (1.7) 200/3088 (6.5)
Low gait speed (%) Calculable 977/4886 (20.0) 694/2880 (24.1)
Missing 458/5344 (8.6) 208/3088 (6.7)
Exhaustion (%) Calculable 1638/5314 (30.8) 816/3077 (26.5)
Missing 30/5344 (0.6) 11/3088 (0.4)
Low activity levels (%) Calculable 1196/5341 (22.4) 709/3088 (23.0)
Missing 3/5344 (0.06) 0/3088 (0)
Table 3 Prevalence of Fried frailty scores in wave 2 and wave 4
of ELSA
Fried Frailty score Wave 2 (N = 4650) Wave 4 (N = 2714)
Mean age
(years) (SD)
70.8 (7.9) 69.3 (6.9)
Male sex (%) 2560 (55.1) 1230 (45.3)
0 (%) Robust (%) 2226 (47.9) 1282 (47.2)
1 (%) Prefrail (%) 1287 (27.7) 1907 (41.0) 747 (27.5) 1108 (40.8)
2 (%) 620 (13.3) 361 (13.3)
3 (%) Frail (%) 349 (7.5) 517 (11.1) 223 (8.2) 324 (11.9)
4 (%) 150 (3.2) 85 (3.1)
5 (%) 18 (0.4) 16 (0.6)
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risk reductions were calculated. Sample sizes for ordinal
regression approach were calculated using the method of
Whitehead [23]. To provide further comparisons with
sample sizes for simple and composite frailty outcomes,
we derived sample size calculations for the Fried frailty
score used as a continuous measure, the four metre walk
speed and the SPPB, which are continuous variables that
have been proposed for use as outcome measures in frailty
trials and are recommended as measures of physical per-
formance for use in clinical practice [24]. For the Fried
score, no anchor-based MCID has been proposed. We
therefore assume a between-group difference of 0.3 points
as seen in Serra-Prat et al. [13], and a SD of 1.2 points at
follow up for those who were prefrail at wave 2 in ELSA.
The MCID for the four-metre walk distance has been esti-
mated, with values between 0.05m/s and 0.10m/s [25].
We used both these values, with a SD of 0.25m/s (based
on values from ELSA at wave 4 for those who were pref-
rail at wave 2, and consistent with other trials for prefrailty
[14, 15]. Finally, the MCID for the SPPB has been esti-
mated at 1 point [26] or 0.5 points [25]. We used both
these values, together with an SD of 2.5 as seen in a previ-
ous trial conducted with functionally impaired older
people [27]. Sample sizes were calculated with and with-
out adjustment for baseline values; a correlation of 0.5 be-
tween baseline and follow up was assumed for adjusted
analyses which is conservative (i.e. lower) than that ob-
served in previous trials using walk speed or SPPB.
Results
Transition probabilities from ELSA data
Data on 5344 participants from wave 2 aged 60 and over
were available; not all participants had data available for
each frailty component, and a complete frailty score was
calculable for 4650 individuals in wave 2, who thus
formed the analysis sample. 390/4650 (8.4%) died be-
tween wave 2 and wave 4; 3088/4650 (66.4%) underwent
and completed the wave 4 assessment. Details of frailty
components and Fried frailty scores at wave 2 and wave
4 are given in Tables 2 and 3 along with age and sex of
the study population and details of missing data for each
frailty score component.
Tables 4 and 5 give the transition probabilities between
wave 2 and wave 4 of ELSA for different baseline frailty
scores and different baseline frailty categories. Of particu-
lar note are the high dropout and death rates in those with
frailty at baseline, and the low rates of reversion from
frailty to the robust state at the four-year follow-up.
Interpolated transition probabilities
Table 6 gives the derived Markov transition probabilities
from baseline prefrailty at 1 and 2 years under three as-
sumed scenarios – firstly that all dropouts are due to ill-
ness, secondly that no dropouts are due to illness, and
thirdly that half the dropouts were due to illness. Rates
of transition to frailty are low at 1 year (9%) and at 2
years (11%) under all scenarios; rates of combined tran-
sition to frailty, death or dropout due to illness are still
relatively low at 1 year (11 to 21%) but reach 16 to 35%
at 2 years depending on the assumptions made about
causes of dropout.
Illustrative sample size calculations
Table 7 shows illustrative sample size calculations for a
hypothetical trial enrolling people with prefrailty at baseline
with a two-year follow up period. Results for different ap-
proaches to frailty transition are presented with a range of
relative risk reductions as the minimum clinically important
Table 4 Change in frailty state between wave 2 and wave 4 of ELSA
Follow up frailty state at Wave 4
Baseline state at Wave 2 n Robust Prefrail Frail Dead Dropped out
Robust 2226 937 (42) 519 (23) 51 (2) 79 (4) 640 (29)
Prefrail 1907 335 (18) 546 (29) 189 (10) 178 (9) 659 (35)
Frail 517 10 (2) 43 (8) 84 (16) 133 (26) 247 (48)
Table 5 Changes in frailty score between wave 2 and wave 4 of ELSA
Follow up frailty score at Wave 4
Baseline score at Wave 2 n 0 1 2 3 4 5 Dead Dropped out
0 2226 937 (42) 407 (18) 112 (5) 37 (2) 13 (1) 1 (0) 79 (4) 640 (29)
1 1287 289 (23) 259 (20) 139 (11) 83 (6) 15 (1) 2 (0) 95 (7) 405 (31)
2 620 46 (7) 67 (11) 81 (13) 65 (11) 17 (3) 7 (1) 83 (13) 254 (41)
3 349 8 (2) 13 (4) 24 (7) 30 (9) 22 (6) 2 (1) 82 (23) 168 (48)
4 150 2 (1) 1 (1) 5 (3) 8 (5) 17 (11) 3 (2) 45 (30) 69 (46)
5 18 0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 1 (6) 6 (33) 10 (56)
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difference in frailty transition rate has not been established.
For comparison, results of sample size calculations for the
Fried frailty score as a continuous variable, the four-metre
walk speed, and the SPPB are shown in Table 8. Projected
sample sizes needed using a composite outcome of transi-
tion to death, frailty or dropout due to illness are less than
a quarter of those needed to detect a simple transition to
the frail state, and sample sizes needed are reduced by a
further factor of three when using an ordinal regression ap-
proach to analysis that uses all transitions including from
prefrail to non-frail status.
Discussion
Findings in context
Our results from a large, representative sample of older
people confirm that transition rates to the frail state from
the robust or prefrail states are low, and that those in the
frail state do not remain under follow-up, instead transi-
tioning to death, or dropping out of follow up because of
frailty and illness. Sample sizes required for trials using
frailty transitions as an outcome are therefore very large,
but the use of a composite outcome of transition to frailty,
death or dropout allows a considerable reduction in the
sample size required, whilst also ensuring that those who
die or drop out still contribute to the analysis. Sample
sizes using the composite outcome in an ordinal logistic
regression analysis were comparable to, or lower than
those needed for commonly-used measures of physical
performance, and were lower than those required when
using the Fried frailty score as a continuous variable.
The transition rates that we observed were compatible
with previous findings; a recent meta-analysis with a
mean 3.9 year follow up found higher rates of transition
from prefrail to frail (18% compared to our finding of
10%) [16], but transition rates were heavily dependent
on the length of follow-up. Our one-year interpolated
estimates for transition from prefrailty to frailty were
similar to that observed at 1 year follow up in the con-
trol arm of a trial enrolling participants with prefrailty
[13], suggesting that our results would be applicable to
trials for this patient group.
Conducting trials for older people poses specific chal-
lenges over and above those usually encountered by trialists.
Recruitment can be challenging due to ageism, illness and
logistical barriers [28], dropout rates are high, and multi-
morbidity and heterogeneity increase variance – hence
Table 6 Interpolated frailty state transition probabilities at one and two years from baseline prefrail state
Baseline state Follow up state 1 year (interpolated) 2 year (interpolated) 4 year (measured)
Assumes all dropouts are due to illness Robust 0.108 0.159 0.176
Prefrail 0.688 0.494 0.286
Frail 0.087 0.113 0.099
Dead/too ill 0.117 0.234 0.439
Assumes no dropouts are due to illness Robust 0.109 0.159 0.176
Prefrail 0.688 0.494 0.286
Frail 0.087 0.113 0.099
Dead 0.019 0.044 0.093
Lost to follow up 0.097 0.190 0.346
Assumes 50% of dropouts are due to illness Robust 0.109 0.159 0.176
Prefrail 0.688 0.494 0.286
Frail 0.088 0.113 0.099
Dead/too ill 0.068 0.139 0.266
Lost to follow up 0.049 0.095 0.173
Table 7 Illustrative sample size calculations; transition from baseline prefrail status; 2 year follow up
To detect relative risk
reduction of:
Transition to frail (per
group)
Transition to frail/dead/too ill (per
group)
Ordinal (robust vs prefrail vs non frail/dead/too ill
(per group)
20% 3621 815 177
25% 2389 558 117
30% 1576 360 87
40% 853 197 55
50% 520 123 38
All two-sided, alpha 0.05, power 0.90
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sample sizes may need to be increased. Recruitment from
institutional care settings poses additional challenges, in-
cluding high death rates, high levels of cognitive impairment
that complicate the process of consent, and organisational
challenges in delivering research outwith traditional health
service structures [29]. Finding outcome measures that can
detect the effect of an intervention without a long period of
follow-up or large numbers of participants is therefore chal-
lenging, but essential if the volume of trials conducted for
older people is to meet the clinical needs of older people
[30]. The proposed composite endpoint developed here ad-
dresses both the issue of sample size and the issue of loss to
follow up due to death or illness, but also has the advantage
of directly measuring the multidimensional construct of
frailty. Measuring frailty transition rates provides an out-
come measure that reflects the longitudinal progression of
frailty experienced by patients. Modifying the natural history
of frailty progression is a key objective of research and prac-
tice in this area, as highlighted by the European Union Ad-
vantAGE joint action plan on frailty (https://advantageja.eu)
and a frailty transition outcome measure could naturally fa-
cilitate conversations between clinicians and patients about
whether to engage with different interventions to prevent or
ameliorate frailty.
Some limitations require comment. We used a large,
representative UK-based cohort to derive transition
rates, and these rates are likely to vary across different
countries and different cohorts. In particular, differences
in age, sex and burden of comorbid disease are likely to
be associated with variation in prevalence of frailty and
different rates of frailty transition. However, these differ-
ences do not invalidate the concept of using a composite
measure. We were unable to differentiate between those
dropping out of ELSA due to illness and those dropping
out from choice; our analyses assume that the majority
dropped out due to illness or disability. The higher rates
of dropout seen with worse baseline frailty status sup-
port this assumption, as do the higher dropout rates
seen with increasing age and the presence of a limiting
illness previously noted in the ELSA cohort [19]. Simi-
larly, we do not have sufficient information from ELSA
to tell whether dropout was due to physical illness or
frailty, or due to progressive cognitive impairment. The
four-year gap between waves 2 and 4 of ELSA may con-
ceal multiple transitions in frailty states, in keeping with
the dynamic nature of the frailty construct. This lack of
temporal resolution can be only partly overcome by the
Markov interpolation method that we used, and our pro-
posed outcome needs to be tested prospectively in a
frailty trial to fully reflect these dynamic changes.
Conclusions
Use of a composite outcome for frailty trials offers re-
duced sample sizes and could ameliorate the effect of high
loss to follow up inherent in such trials due to death and
illness. As a next step, the acceptability of the composite
endpoint to both people living with frailty or prefrailty,
and to clinicians caring for this group of patients should
be established. The outcome will be of use in shared deci-
sion making only if it carries meaning to those who will
use the evidence. Secondly, the degree of change in transi-
tion rates that would change the decision to recommend a
treatment should be established. This metric – similar to
the MCID for continuous outcomes, is poorly defined for
most categorical measures used in trials yet is essential to
derive meaningful sample size calculations. Finally, the
composite outcome should be applied to existing datasets
from frailty trials to test how the proposed composite
measure might work in the real world. Successful practical
application and user acceptability will confirm or refute
the usefulness of this approach.
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